Hancock Jaffe Laboratories, Inc. Announces Pricing of Initial Public Offering
31 5월 2018 - 8:30PM
Hancock Jaffe Laboratories, Inc. (“HJLI”), a company specializing
in bioprosthetic medical devices to establish improved standards of
care for treating cardiac and vascular diseases, today announced
the pricing of its initial public offering of 1,500,000 units, each
unit consisting of one share of common stock and a warrant to
purchase one share of common stock, at an initial public offering
price of $5.00 per unit, before underwriting discounts and
commissions. HJLI has also granted the underwriter a 45-day option
to purchase an additional 225,000 units at the initial public
offering price.
The shares of common stock and warrants
underlying the units have been approved for listing on The Nasdaq
Capital Market and are expected to begin trading under the ticker
symbols “HJLI” and “HJLIW,” respectively, on May 31, 2018. The
offering is expected to close on June 4, 2018, subject to customary
closing conditions.
Network 1 Financial Securities, Inc. is acting
as sole book-running manager for the offering.
A registration statement on Form S-1, including
a prospectus, which is preliminary and subject to completion,
relating to the offering has been filed with, and declared
effective by, the U.S. Securities and Exchange Commission on May
30, 2018. The offering of these units will be made only by means of
a prospectus. Copies of the prospectus may be obtained from Network
1 Financial Securities, Inc., 2 Bridge Ave #241, Red Bank, NJ
07701, or by e-mail at info@netw1.com, or by telephone at 1-(800)
886-7007.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy, nor shall there be
any sale of these securities in any state or jurisdiction in which
such offer, solicitation, or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Hancock Jaffe Laboratories, Inc.
HJLI specializes in developing and manufacturing
bioprosthetic medical devices to establish improved standards of
care for treating cardiac and vascular diseases. HJLI currently has
three product candidates: the porcine tissue based VenoValveÒ,
which is intended to be surgically implanted in the deep venous
system of the leg to treat Chronic Venue Insufficiency; the
CoreoGraftÒ, a bovine tissue based off the shelf conduit intended
to be used for coronary artery bypass surgery, and a porcine tissue
based heart valve, which based upon its relatively small size and
increased output, is an ideal candidate for pediatric aortic/mitral
valve replacement.
Forward-Looking Statements
This press release contains certain
forward-looking statements, including statements with regard to
HJLI’s proposed initial public offering. Words such as “expects,”
“anticipates” and “intends” or similar expressions are intended to
identify forward-looking statements. These forward-looking
statements are subject to the inherent uncertainties in predicting
future results and conditions and no assurance can be given that
the proposed initial public offering discussed above will be
completed on the terms described. Completion of the proposed
initial public offering and the terms thereof are subject to
numerous factors, many of which are beyond the control of HJLI,
including, without limitation, failure of customary closing
conditions and the risk factors and other matters set forth in the
prospectus included in the registration statement in the form last
filed with the U.S. Securities and Exchange Commission. HJLI
undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as may be required by law.
HJLI Press Contacts:
Robert Berman, CEOTel: 949-261-2900Email: rob@HJLInc.com
Hancock Jaffe Laboratories (NASDAQ:HJLIW)
과거 데이터 주식 차트
부터 8월(8) 2024 으로 9월(9) 2024
Hancock Jaffe Laboratories (NASDAQ:HJLIW)
과거 데이터 주식 차트
부터 9월(9) 2023 으로 9월(9) 2024